Cancer is clearly a genetic disease, as demonstrated by the complexity of cancer genomes that can carry hundreds of mutations in oncogenes and tumor suppressor genes, collectively known as cancer ...

The 5-year survival rate for pancreatic ductal adenocarcinoma (PDA) is currently 13%, making it one of the most fatal human malignancies; to date, PDA is the third leading cause of cancer-related ...

The term “alkylating agent” has been defined and a detailed discussion made of the mechanisms (Sn1 and Sn2) by which they interact with nucleophilic centers. The various nucleophiles likely to be ...

PROteolysis-TArgeting Chimera (PROTAC) molecules are a novel class of therapies being developed for cancer treatment and other life-threatening diseases driven by the aberrant expression of a ...

These studies demonstrate that certain KRAS G12C inhibitors effectively target all RAS G12C mutations and that sotorasib specifically is a potent NRAS G12C inhibitor capable of driving clinical ...

Abstract. The Hippo pathway, a critical cell proliferation regulator, remains an underexplored oncogenic pathway in precision oncology. It is executed through YAP1/TAZ co-activators and the TEAD ...

Abstract. KRASG12C inhibitors, such as sotorasib and adagrasib, have revolutionized cancer treatment for patients with KRASG12C-mutant tumors. However, patients receiving these agents as monotherapy ...

The clinical benefit of isoform-selective inhibition of PI3Kα has been demonstrated with alpelisib in PI3Kα-mutant cancers. Alpelisib is an orthosteric inhibitor that shows equipotent inhibition of ...

Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRAS G12D) being the most common. Here, we tested the ...

Pancreatic ductal adenocarcinoma (PDAC) is the third most common cause of cancer-related death in the United States, with a dismal 5-year survival rate of 10% (1). Thus, patients with PDAC are in ...

We used the French National Health Data System (SNDS), covering 99% of the French population since 2006. Incident cases of pancreatic cancer, identified between 2014 and 2018, were matched with up to ...

AbstractPurpose:. Anlotinib has achieved good results in clinical trials of a variety of cancers. However, the effects of anlotinib on the tumor microenvironment (TME) and systemic immunity have not ...